IQVIA (NYSE:IQV) Stock Unloaded Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of IQVIA Holdings Inc. (NYSE:IQV). In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $50,001 and $100,000 in IQVIA stock on March 16th. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Exact Sciences (NASDAQ:EXAS) on 3/24/2026.
• Sold $50,001 – $100,000 in shares of Prologis (NYSE:PLD) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of T. Rowe Price Group (NASDAQ:TROW) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 3/20/2026.
• Sold $500,001 – $1,000,000 in shares of Texas Instruments (NASDAQ:TXN) on 3/18/2026.
• Sold $500,001 – $1,000,000 in shares of Smartstop Self Storage REIT (NYSE:SMA) on 3/18/2026.
• Sold $50,001 – $100,000 in shares of BlackRock MuniAssets Fund (NYSE:MUA) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Cognizant Technology Solutions (NASDAQ:CTSH) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Invesco (NYSE:IVZ) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Becton, Dickinson and Company (NYSE:BDX) on 3/17/2026.

IQVIA Stock Performance

IQV opened at $170.66 on Tuesday. The company has a market cap of $28.96 billion, a PE ratio of 21.71, a price-to-earnings-growth ratio of 1.67 and a beta of 1.39. The stock has a 50-day moving average of $178.70 and a 200-day moving average of $204.76. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on IQV shares. BMO Capital Markets set a $250.00 price target on IQVIA in a research note on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. UBS Group cut their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Citigroup cut their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Finally, Mizuho set a $215.00 price objective on IQVIA in a research report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $229.13.

Hedge Funds Weigh In On IQVIA

Large investors have recently added to or reduced their stakes in the company. Boston Partners bought a new stake in shares of IQVIA in the 3rd quarter valued at approximately $676,698,000. Norges Bank bought a new position in shares of IQVIA during the 4th quarter worth approximately $497,445,000. Victory Capital Management Inc. lifted its position in shares of IQVIA by 2,628.1% during the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after buying an additional 1,614,063 shares during the period. Orbis Allan Gray Ltd lifted its position in shares of IQVIA by 96.5% during the 4th quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock worth $428,525,000 after buying an additional 933,554 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of IQVIA by 130.2% during the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after buying an additional 879,701 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.